Evidence map›Paper›PMID 41852520›Full record

ArticleInternational journal of pharmaceutics: X2026

Besifloxacin-eluting contact lens with sustained drug delivery and enhanced bioavailability.

Liangju Kuang, Nikolay Boychev, Lin Chen, Amy E Ross, Levi N Kanu, Maria Miura, Cheng Peng, Ann Yung, Vincent Yeung, Eric G Romanowski and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Liangju KuangDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, United States.
Nikolay BoychevDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, United States.
Lin ChenDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, United States.
Amy E RossDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, United States.
Levi N KanuDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, United States.
Maria MiuraDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, United States.
Cheng PengDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, United States.
Ann YungDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, United States.
Vincent YeungDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, United States.
Eric G RomanowskiThe Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Vision Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Reza DanaDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, United States.
Daniel S KohaneLaboratory for Biomaterials and Drug Delivery, Department of Anesthesiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.
Joseph B CiolinoDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial keratitis is a prevalent and sight-threatening ocular infection. Current treatments typically involve intensive antibiotic eye drops or ointments; however, their effectiveness is limited by poor corneal penetration, low bioavailability, and suboptimal patient adherence. These limitations are particularly pronounced for besifloxacin, a fourth-generation fluoroquinolone with broad-spectrum antibacterial activity but low octanol-water partition coefficient and poor aqueous solubility. Here, we present a besifloxacin-eluting contact lens (BXF-CL) engineered to enhance corneal drug penetration and sustain therapeutic antibiotic levels. BXF-CLs were fabricated by encapsulating a thin, drug-loaded polymer film-composed of physiologically inert polymers (ethylcellulose and Eudragit® RSPO)-within the periphery of soft contact lenses

Indexed as

Bacterial keratitisBesifloxacinDrug-eluting contact lensIntraocular drug penetrationOcular antibiotic deliveryPharmacokineticsStability

Identifiers

PMID41852520
PMCPMC12994077

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.